| Patents for C12N 15 - Mutation or genetic engineering; Dna or rna concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor (402,210) |
|---|
| 01/22/2009 | US20090023670 Regulation of Transgene Expression by RNA Interference |
| 01/22/2009 | US20090023660 Novel Hemopoietin Receptor Protein, NR12 |
| 01/22/2009 | US20090023659 Using cell surface adhesion proteins specific immunoglobulin to target therapeutics to tumorous; immunodiagnostics; immunotherapy |
| 01/22/2009 | US20090023654 Axmi-008, a delta-endotoxin gene and methods for its use |
| 01/22/2009 | US20090023653 Method of using broad-spectrum delta-endotoxins |
| 01/22/2009 | US20090023651 Inhibitors of human plasmin derived from the kunitz domains |
| 01/22/2009 | US20090023649 for treating diseases relating to angiogenesis; fusion protein possesses ribosome inactivating activity and ability to bind to cellular vascular endothelial growth factor (VEGF) receptors |
| 01/22/2009 | US20090023647 Method of producing biologically active human acidic fibroblast growth factor and its use in promoting angiogenesis |
| 01/22/2009 | US20090023646 GHRH analogues |
| 01/22/2009 | US20090023645 AIB1, a novel steroid receptor co-activator |
| 01/22/2009 | US20090023635 Factor VII or VIIa - Like Molecules |
| 01/22/2009 | US20090023602 Binding polypeptides with restricted diversity sequences |
| 01/22/2009 | US20090023599 Use of antisense oligonucleotide libraries for identifying gene function |
| 01/22/2009 | US20090023593 In situ cloning from pathological tissue specimens |
| 01/22/2009 | US20090023592 System for identifying and analyzing expression of are-containing genes |
| 01/22/2009 | US20090023226 Variant Integrin Polypeptides and Uses Thereof |
| 01/22/2009 | US20090023224 Vascular endothelial growth factor 2 |
| 01/22/2009 | US20090023216 Double-Stranded Oligonucleotides |
| 01/22/2009 | US20090023215 Novel reagents for transfection of eukaryotic cells |
| 01/22/2009 | US20090023207 CHROMOSOME 3p21.3 GENES ARE TUMOR SUPPRESSORS |
| 01/22/2009 | US20090023196 Stocks of replication-deficient adenovirus |
| 01/22/2009 | US20090023191 Gene RCS 23 |
| 01/22/2009 | US20090023188 Using Pasteurella; genetic engineering; purified nucleic acid segments |
| 01/22/2009 | US20090023185 Avidin Mutants |
| 01/22/2009 | US20090023184 Novel Tachykinin Peptides, Precursor Peptides Thereof And Genes Encoding The Same |
| 01/22/2009 | US20090023172 identifying antifungal agents based on fungal GTP cyclohydrolase II; adding GTP, NAD+ and formate dehydrogenase to a sample comprising GTP cyclohydrolase II or I, determining production of NADH, and correlating the production of NADH with GTP I or II activity |
| 01/22/2009 | US20090023162 Method for the identification of atypical p-anca |
| 01/22/2009 | US20090023160 Antibodies specific for CYP1B1 |
| 01/22/2009 | US20090023154 Relating to marking |
| 01/22/2009 | US20090023153 Targeted modification of chromatin structure |
| 01/22/2009 | US20090023152 Transcription factor MHC class II genes, substances capable of inhibiting this transcription factor and medical uses of these substances |
| 01/22/2009 | US20090023147 Diagnostics and therapeutics for osteoporosis |
| 01/22/2009 | US20090023145 Methods of diagnosing or prognosing Alzheimer's disease |
| 01/22/2009 | US20090023140 Crosslinking agent, crosslinking method, method of controlling gene expression, and method of examining gene function |
| 01/22/2009 | US20090023136 HSD3B1 sequence variants |
| 01/22/2009 | US20090023131 Circuit arrangement for injecting nucleic acids and other biologically active molecules into the nucleus of higher eucaryontic cells using electrical current |
| 01/22/2009 | US20090022873 Genes Useful for the Industrial Production of Citric Acid |
| 01/22/2009 | US20090022783 siRNA MICROBICIDES FOR PREVENTING AND TREATING DISEASES |
| 01/22/2009 | US20090022762 Polyvalent influenza virus-like particle (VLP) compositions |
| 01/22/2009 | US20090022753 Surface proteins of streptococcus pyogenes |
| 01/22/2009 | US20090022748 Unique associated Kaposi's sarcoma virus sequences and uses thereof |
| 01/22/2009 | US20090022747 B7-h3 and b7-h4, novel immunoregulatory molecules |
| 01/22/2009 | US20090022746 Complexes for transferring nucleic acids into cells |
| 01/22/2009 | US20090022743 Peptides Effective in the Treatment of Tumors and Other Conditions Requiring the Removal or Destruction of Cells |
| 01/22/2009 | US20090022742 Compounds and methods for diagnosis and immunotherapy of tuberculosis |
| 01/22/2009 | US20090022738 Multispecific deimmunized CD3-binders |
| 01/22/2009 | US20090022736 Monoclonal Antibodies That Specifically Bind To And Neutralize Bacillus Anthracis Toxin, Compositions, And Methods Of Use |
| 01/22/2009 | US20090022735 Receptor Binding Polypeptides |
| 01/22/2009 | US20090022725 antagonist antibody that blocks binding of IL-17; degenerative cartilaginous disorders and other inflammatory diseases |
| 01/22/2009 | US20090022724 Attractin/mahogany-like polypeptides, polynucleotides, antibodies and methods of use thereof |
| 01/22/2009 | US20090022721 Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor |
| 01/22/2009 | US20090022716 Combination methods of inhibiting tumor growth with a vascular endothelial growth factor receptor antagonist |
| 01/22/2009 | US20090022714 Combination methods of inhibiting tumor growth with a vascular endothelial growth factor receptor antagonist |
| 01/22/2009 | US20090022713 Anti-pro87299 antibodies |
| 01/22/2009 | US20090022712 Compositions and Methods for Inhibiting Leukocyte Function |
| 01/22/2009 | US20090022710 Nuclear factor of activated t cells receptor |
| 01/22/2009 | US20090022709 Control of sorbose utilization genes and uses thereof |
| 01/22/2009 | US20090022708 Trefoil Factors and Methods of Treating Proliferation Disorders Using Same |
| 01/22/2009 | US20090022705 Chloroplasts engineered to express pharmaceutical proteins in edible plants |
| 01/22/2009 | US20090022701 Administering to the patient an amount of CLN2 protein (Neuronal ceroid lipofuscinoses (NCLs)) effective to reduce or eliminate the symptoms caused by the deficiencyl in CLN2 protein; Central nervous system disorders |
| 01/22/2009 | US20090022699 Method Of Genotypically Modifying Cells By Administration Of RNA |
| 01/22/2009 | US20090022690 Bacterial translocation inhibitor and method of inhibiting bacterial translocation |
| 01/22/2009 | US20090022659 Antibodies to TNF alpha and use thereof |
| 01/22/2009 | US20090022658 Modified antibodies and methods of use |
| 01/22/2009 | US20090022657 Novel CXCL8 antagonists |
| 01/22/2009 | US20090022623 Peptides Capable of Functioning as Mimotopes for Hormonal Analytes |
| 01/22/2009 | DE102007035109A1 Alcohol dehydrogenase for producing R-enantiomerically secondary alcohol and separating secondary alcohol from racemic mixture, has amino acid sequence of hydroxybutyrate dehydrogenase |
| 01/22/2009 | CA2729011A1 Varicella zoster virus-virus like particles (vlps) and antigens |
| 01/22/2009 | CA2696437A1 Production and use of epitope-tagged hepatitis c virus particle |
| 01/22/2009 | CA2695161A1 D4 desaturases and d5 elongases |
| 01/22/2009 | CA2693956A1 Influenza virus-like particles (vlps) comprising hemagglutinin produced within a plant |
| 01/22/2009 | CA2693712A1 Methods and compositions for treating brain diseases |
| 01/22/2009 | CA2693553A1 Compositions and methods for treating tumors, fibrosis, and pulmonary alveolar proteinosis |
| 01/22/2009 | CA2693449A1 Nucleic acid sequences for the amplification and detection of respiratory viruses |
| 01/22/2009 | CA2693448A1 Improved selex and photoselex |
| 01/22/2009 | CA2693365A1 Novel arabinose-fermenting eukaryotic cells |
| 01/22/2009 | CA2693255A1 Anti-cd79b antibodies and immunoconjugates and methods of use |
| 01/22/2009 | CA2693137A1 Engineered scfv against bovine herpes virus type i |
| 01/22/2009 | CA2693059A1 Method and apparatus using electric field for improved biological assays |
| 01/22/2009 | CA2692819A1 Humanized anti-cd79b antibodies and immunoconjugates and methods of use |
| 01/22/2009 | CA2692710A1 Genetic basis for improved milling performance |
| 01/22/2009 | CA2692693A1 Optimized dna and protein sequence of an antibody to improve quality and yield of bacterially expressed antibody fusion proteins |
| 01/22/2009 | CA2692650A1 Transgenic plants with increased stress tolerance and yield |
| 01/22/2009 | CA2691406A1 Preprocalcitonin antigen t epitopes |
| 01/22/2009 | CA2690939A1 Method for generating stable cell lines expressing high levels of a protein of interest |
| 01/22/2009 | CA2690923A1 Increasing grain yield through targeted reduction in ethylene signaling |
| 01/21/2009 | EP2017624A1 Filter-carrying micro plate |
| 01/21/2009 | EP2017357A1 DNA diagnostics based on mass spectrometry |
| 01/21/2009 | EP2017355A1 Gene associated with arteriosclerotic disease, and use thereof |
| 01/21/2009 | EP2017348A1 Method of producing L-lysine by fermentation |
| 01/21/2009 | EP2017345A1 Nucleotide sequences and polypeptides encoded thereby useful for inreasing plant size and increasing the number and size of leaves |
| 01/21/2009 | EP2017344A1 Production of itaconic acid |
| 01/21/2009 | EP2017343A2 Protein A based binding domains with desirable activities |
| 01/21/2009 | EP2017342A1 Recombinant allergen with reduced enzymatic activity |
| 01/21/2009 | EP2017341A2 Apo-2 ligand |
| 01/21/2009 | EP2017340A1 Positive controls for expression modulating experiments |
| 01/21/2009 | EP2017339A1 Nucleic acid purification instrument |
| 01/21/2009 | EP2017338A1 Muscle-specific expression vectors |
| 01/21/2009 | EP2017337A1 Human tumor necrosis factor receptors |
| 01/21/2009 | EP2017336A1 Marker for selecting aphanomyces cochlioides-resistant variety and selection method therefor |